Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts | Zendy

Franck Assayag | Zendy; Nicolás André | Zendy; Sophie Vacher | Zendy; Catherine Dehainault | Zendy; Ivan Bièche | Zendy; Didier Meseure | Zendy; Isabelle Aerts | Zendy; Nathalie Cassoux | Zendy; Claude Houdayer | Zendy; François Doz | Zendy; Didier Decaudin | Zendy

Open Access

Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts

Author(s) -

Franck Assayag,

Nicolás André,

Sophie Vacher,

Catherine Dehainault,

Ivan Bièche,

Didier Meseure,

Isabelle Aerts,

Nathalie Cassoux,

Claude Houdayer,

François Doz,

Didier Decaudin

Publication year - 2016

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.15-18725

Subject(s) - carboplatin , bevacizumab , medicine , retinoblastoma , chemotherapy , oncology , biology , cisplatin , biochemistry , gene

Retinoblastoma (Rb) is a rare childhood cancer of the retina with a survival rate of 95% in children living in high-income countries, after appropriate therapies such as chemotherapy, local ophthalmologic treatment, and radiotherapy. However, due to inactivation of the RB1 gene, all bilateral and almost 15% of unilateral retinoblastoma patients have a higher risk of s econdary cancers, especially sarcomas. Hence, new nonmutagen treatments are warranted. Therefore, we investigated the efficacy of therapy using anti-VEGF antibody bevacizumab, either alone or with carboplatin, in well-characterized Rb patient-derived xenografts (PDXs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research